Top

Published in:

01-12-2020 | Pancreatic Cancer | Research article

Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome

Authors: Marius Freytag, Ulrich Herrlinger, Stefan Hauser, Franz G. Bauernfeind, Maria A. Gonzalez-Carmona, Jennifer Landsberg, Jens Buermann, Hartmut Vatter, Tobias Holderried, Thorsten Send, Martin Schumacher, Arne Koscielny, Georg Feldmann, Mario Heine, Dirk Skowasch, Niklas Schäfer, Benjamin Funke, Michael Neumann, Ingo G. H. Schmidt-Wolf

Published in: BMC Cancer | Issue 1/2020

Abstract

Background

This analysis aims at evaluating the impact of multidisciplinary tumor boards on clinical outcome of multiple tumor entities, the effect of the specific number of multidisciplinary tumor boards and potential differences between the tumor entities.

Methods

By a matched-pair analysis we compared the response to treatment, overall survival, relapse or disease free survival and progression free survival of patients whose cases were discussed in a tumor board meeting with patients whose cases were not. It was performed with patients registered in the cancer registry of the University of Bonn and diagnosed between 2010 and 2016. After the matching process with a pool of 7262 patients a total of 454 patients with 66 different tumor types were included in this study.

Results

First, patients with three or more multidisciplinary tumor board meetings in their history show a significantly better overall survival than patients with no tumor board meeting. Second, response to treatment, relapse free survival and time to progression were not found to be significantly different. Third, there was no significant difference for a specific tumor entity.

Conclusion

This study revealed a positive impact of a higher number of multidisciplinary tumor boards on the clinical outcome. Also, our analysis hints towards a positive effect of multidisciplinary tumor boards on overall survival.

Bilfinger TV, Albano D, Perwaiz M, Keresztes R, Nemesure B. Survival outcomes among lung Cancer patients treated using a multidisciplinary team approach. Clin Lung Cancer. 2018;19:346–51. https://doi.org/10.1016/j.cllc.2018.01.006.CrossRefPubMed

Stone E, Rankin N, Kerr S, Fong K, Currow DC, Phillips J, et al. Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study. Lung Cancer. 2018;124:199–204. https://doi.org/10.1016/j.lungcan.2018.07.032.CrossRefPubMed

Tamburini N, Maniscalco P, Mazzara S, Maietti E, Santini A, Calia N, et al. Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study. Eur J Cardiothorac Surg. 2018;53:1199–204. https://doi.org/10.1093/ejcts/ezx464.CrossRefPubMed

Liao C-T, Kang C-J, Lee L-Y, Hsueh C, Lin C-Y, Fan K-H, et al. Association between multidisciplinary team care approach and survival rates in patients with oral cavity squamous cell carcinoma. Head Neck. 2016;38(Suppl 1):E1544–53. https://doi.org/10.1002/hed.24276.CrossRefPubMed

Liu JC, Kaplon A, Blackman E, Miyamoto C, Savior D, Ragin C. The impact of the multidisciplinary tumor board on head and neck cancer outcomes. Laryngoscope. 2019. https://doi.org/10.1002/lary.28066.

Sinn DH, Choi G-S, Park HC, Kim JM, Kim H, Song KD, et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One. 2019;14:e0210730. https://doi.org/10.1371/journal.pone.0210730.CrossRefPubMedPubMedCentral

Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, Reddick M, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2014;21:1287–95. https://doi.org/10.1245/s10434-013-3413-8.CrossRefPubMed

Kesson EM, Allardice GM, George WD, Burns HJG, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012;344:e2718. https://doi.org/10.1136/bmj.e2718.CrossRefPubMedPubMedCentral

Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim K-H, Mullady DK, et al. Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. HPB (Oxford). 2017;19:133–9. https://doi.org/10.1016/j.hpb.2016.11.002.CrossRef

10.

Palmer G, Martling A, Cedermark B, Holm T. Preoperative tumour staging with multidisciplinary team assessment improves the outcome in locally advanced primary rectal cancer. Color Dis. 2011;13:1361–9. https://doi.org/10.1111/j.1463-1318.2010.02460.x.CrossRef

11.

Engelhardt M, Selder R, Pandurevic M, Möller M, Ihorst G, Waldschmidt J, et al. Multidisziplinäre Tumorboards: Fakten und Zufriedenheitsanalyse eines unverzichtbaren Instruments von Tumorzentren. TumorDiagn u Ther. 2017;38:447–56. https://doi.org/10.1055/s-0043-108593.CrossRef

12.

Albany C, Adra N, Snavely AC, Cary C, Masterson TA, Foster RS, et al. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors. Ann Oncol. 2018;29:341–6. https://doi.org/10.1093/annonc/mdx731.CrossRefPubMed

13.

Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev. 2016;42:56–72. https://doi.org/10.1016/j.ctrv.2015.11.007.CrossRefPubMed

14.

Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ. Tumor boards and the quality of cancer care. J Natl Cancer Inst. 2013;105:113–21. https://doi.org/10.1093/jnci/djs502.CrossRefPubMedPubMedCentral

15.

Hollunder S, Herrlinger U, Zipfel M, Schmolders J, Janzen V, Thiesler T, et al. Cross-sectional increase of adherence to multidisciplinary tumor board decisions. BMC Cancer. 2018;18:936. https://doi.org/10.1186/s12885-018-4841-4.CrossRefPubMedPubMedCentral

Title: Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome
Authors: Marius Freytag
Ulrich Herrlinger
Stefan Hauser
Franz G. Bauernfeind
Maria A. Gonzalez-Carmona
Jennifer Landsberg
Jens Buermann
Hartmut Vatter
Tobias Holderried
Thorsten Send
Martin Schumacher
Arne Koscielny
Georg Feldmann
Mario Heine
Dirk Skowasch
Niklas Schäfer
Benjamin Funke
Michael Neumann
Ingo G. H. Schmidt-Wolf
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Pancreatic Cancer
Pancreatic Cancer
Published in: BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-020-06809-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Analyses of metastasis-associated genes in IDH wild-type glioma

Coffee drinking and cancer risk: an umbrella review of meta-analyses of observational studies

Bacteriocin production by mucosal bacteria in current and previous colorectal neoplasia

Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma

Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis

Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing

Keynote webinar | Spotlight on antibody–drug conjugates in cancer